Department of Pharmacy Practice, School of Pharmacy, Lebanese American University, Byblos Campus, PO Box 36, 13-5053 Beirut, Lebanon.
World J Gastroenterol. 2010 Feb 28;16(8):982-6. doi: 10.3748/wjg.v16.i8.982.
To assess the appropriateness of the indication and route of administration of proton-pump-inhibitors (PPIs) and their associated cost impact.
Data collection was performed prospectively during a 6-mo period on 340 patients who received omeprazole intravenously during their hospital stay in non-intensive care floors. Updated guidelines were used to assess the appropriateness of the indication and route of administration.
Complete data collection was available for 286 patients which were used to assess intravenous (IV) PPIs utilization. Around 88% of patients were receiving PPIs for claimed stress ulcer prophylaxis (SUP) indication; of which, only 17% met the guideline criteria for SUP indication, 14% met the criteria for non-steroidal-anti-inflammatory drugs-induced ulcer prophylaxis, while the remaining 69% were identified as having an unjustified indication for PPI use. The initiation of IV PPIs was appropriate in 55% of patients. Half of these patients were candidates for switching to the oral dosage form during their hospitalization, while only 36.7% of these patients were actually switched. The inappropriate initiation of PPIs via the IV route was more likely to take place on the medical floor than the surgical floor (53% vs 36%, P = 0.003). The cost analysis associated with the appropriateness of the indication for PPI use as well as the route of administration of PPI revealed a possible saving of up to $17,732.5 and $14,571, respectively.
This study highlights the over-utilization of IV PPIs in non-intensive care unit patients. Restriction of IV PPI use for justified indications and route of administration is recommended.
评估质子泵抑制剂(PPIs)的适应证和给药途径的适宜性及其相关成本影响。
在非重症监护病房住院期间接受静脉注射奥美拉唑的 340 例患者中,前瞻性地进行了为期 6 个月的数据收集。使用更新的指南评估适应证和给药途径的适宜性。
286 例患者可用于评估静脉(IV)PPI 的使用情况,可完整收集数据。约 88%的患者因声称的应激性溃疡预防(SUP)适应证接受 PPI 治疗;其中,仅 17%符合 SUP 适应证指南标准,14%符合非甾体抗炎药诱导性溃疡预防标准,而其余 69%被认为是 PPI 使用无正当适应证。IV PPI 的起始治疗在 55%的患者中是适宜的。这些患者中有一半在住院期间有转换为口服剂型的适应证,而实际上只有 36.7%的患者进行了转换。不合理地通过 IV 途径起始 PPI 更可能发生在内科病房而不是外科病房(53%比 36%,P = 0.003)。与 PPI 适应证适宜性以及 PPI 给药途径相关的成本分析显示,可能最多可节省 17732.5 美元和 14571 美元。
本研究强调了非重症监护病房患者中 IV PPI 的过度使用。建议限制 IV PPI 仅用于有合理适应证和给药途径的情况。